-
UBS Upgrades Walgreens Boots Alliance, Says Valuation Reflects Heightened Near-Term Risks
Monday, April 6, 2020 - 3:33pm | 262Read More...Although the coronavirus (COVID-19) outbreak has introduced greater near-term risks for Walgreens Boots Alliance Inc (NASDAQ: WBA), the company’s same-store sales are likely to be fairly resilient once activity levels begin returning to normal, according to UBS. The Walgreens Analyst UBS...
-
Teva Analyst Says Shares Are Pricing In Too Much Risk
Monday, April 6, 2020 - 11:37am | 470Read More...Teva Pharmaceutical Industries Ltd (NYSE: TEVA), which is beset by fundamental and legal woes, is entering a recovery phase, according to UBS Securities. The Teva Analyst Analyst Kevin Caliendo upgraded Teva from Neutral to Buy and lowered the price target from $14 to $12. The Teva Thesis...
-
CVS Turnaround Plan May Be 'Good Enough,' But Timeline Is The Question
Wednesday, June 5, 2019 - 3:27pm | 651Read More...CVS Health Corp (NYSE: CVS) laid out its ideas for growing earnings growth from the low single digits expected next year, giving analysts a look at a plan that includes a turnaround in its retail long-term care business, growth at its acquired health insurer Aetna and faster-than-expected ramp up...
-
Needham Sees A Healthy Risk-Reward For CVS Health
Friday, November 10, 2017 - 1:29pm | 430Read More...CVS Health Corp (NYSE: CVS)'s proposed acquisition of health insurer Aetna Inc (NYSE: AET) could be seen as a move to better defend itself should Amazon.com, Inc. (NASDAQ: AMZN) flex its muscles and enter the drug space. The Analyst Needham's Kevin Caliendo. The Rating Caliendo upgraded...
